Tesaro, Inc.

This study is the first to test TSR-022, an experimental antibody that targets a protein called TIM-3 on immune cells, in people with advanced solid tumors. The trial has two parts: first, finding the safest dose, and second, seeing how well the drug works when given alone or wit…

This study is testing an experimental drug called dostarlimab (TSR-042) in people with advanced solid tumors who have run out of standard treatment options. The drug works by helping the immune system attack cancer cells. The study has two parts: first, finding the safest dose, a…

This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 785 participants will receive either dostarlimab plus chemo or a placebo plus che…

This study tests a daily pill called niraparib for people with advanced ovarian cancer who have finished their first round of chemotherapy. The goal is to see if taking niraparib can keep the cancer from growing or coming back longer than a placebo. About 733 participants with st…

This phase 3 trial tests whether adding two drugs (dostarlimab and niraparib) to standard chemotherapy can slow the growth of advanced ovarian cancer better than standard treatment alone. About 1,400 women with newly diagnosed stage III or IV ovarian cancer will participate. The …